Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

January 31, 2033

Conditions
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast CancerAdvanced Breast Cancer
Interventions
DRUG

RYZ101

Ac-225

Trial Locations (23)

10016

NOT_YET_RECRUITING

Research Facilty, New York

10021

RECRUITING

Research Facility, New York

14203

NOT_YET_RECRUITING

Research Facility, Buffalo

15213

NOT_YET_RECRUITING

Research Facility, Pittsburgh

19104

NOT_YET_RECRUITING

Research Facility, Philadelphia

23502

RECRUITING

Research Facility, Norfolk

30322

NOT_YET_RECRUITING

Research Facility, Atlanta

32224

NOT_YET_RECRUITING

Research Facility, Jacksonville

44195

NOT_YET_RECRUITING

Research Facility, Cleveland

46202

RECRUITING

Research Facility, Indianapolis

48202

NOT_YET_RECRUITING

Research Facility, Detroit

55905

NOT_YET_RECRUITING

Research Facility, Rochester

63130

RECRUITING

Research Facility, St Louis

68124

RECRUITING

Research Facility, Omaha

75246

RECRUITING

Research Facility, Dallas

77024

RECRUITING

Research Facility, Houston

80504

RECRUITING

Research Facility, Longmont

84132

RECRUITING

Research Facilty, Salt Lake City

85054

NOT_YET_RECRUITING

Research Facility, Phoenix

90404

RECRUITING

Research Facility, Santa Monica

92618

RECRUITING

Research Facility, Irvine

98109

RECRUITING

Research Facility, Seattle

02215

RECRUITING

Research Facility, Boston

All Listed Sponsors
lead

RayzeBio, Inc.

INDUSTRY